Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy

被引:33
作者
Bonsang-Kitzis, Helene [1 ,6 ,7 ]
Chaltier, Leonor [2 ]
Belin, Lisa [2 ]
Savignoni, Alexia [2 ]
Rouzier, Roman [1 ]
Sablin, Marie-Paule [3 ]
Lerebours, Florence [3 ]
Bidard, Francois-Clement [3 ]
Cottu, Paul [3 ]
Sastre-Garau, Xavier [4 ]
Lae, Marick [4 ]
Pierga, Jean-Yves [3 ,5 ]
Reyal, Fabien [1 ,6 ,7 ]
机构
[1] Inst Curie, Dept Surg, Paris, France
[2] Inst Curie, Dept Biostat, Paris, France
[3] Inst Curie, Dept Med Oncol, Paris, France
[4] Inst Curie, Dept Tumor Biol, Paris, France
[5] Paris Descartes Univ, Paris, France
[6] Inst Curie, Translat Res Dept, Residual Tumor & Response Treatment Lab, Paris, France
[7] INSERM, Immun & Canc UMR932, Paris, France
关键词
PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; PREOPERATIVE CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; MOLECULAR SUBTYPES; DOSE INTENSITY; OBESE-PATIENTS; TUMOR SIZE; EXPRESSION; SURVIVAL;
D O I
10.1371/journal.pone.0144359
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
070301 [无机化学]; 070403 [天体物理学]; 070507 [自然资源与国土空间规划学]; 090105 [作物生产系统与生态工程];
摘要
Background Triple-negative breast cancers (TNBC) are a specific subtype of breast cancers with a particularly poor prognosis. However, it is a very heterogeneous subgroup in terms of clinical behavior and sensitivity to systemic treatments. Thus, the identification of risk factors specifically associated with those tumors still represents a major challenge. A therapeutic strategy increasingly used for TNBC patients is neoadjuvant chemotherapy (NAC). Only a subset of patients achieves a pathologic complete response (pCR) after NAC and have a better outcome than patients with residual disease. Purpose The aim of this study is to identify clinical factors associated with the metastatic-free survival in TNBC patients who received NAC. Methods We analyzed 326 cT1-3N1-3M0 patients with ductal infiltrating TNBC treated by NAC. The survival analysis was performed using a Cox proportional hazard model to determine clinical features associated with prognosis on the whole TNBC dataset. In addition, we built a recursive partitioning tree in order to identify additional clinical features associated with prognosis in specific subgroups of TNBC patients. Results We identified the lymph node involvement after NAC as the only clinical feature significantly associated with a poor prognosis using a Cox multivariate model (HR = 3.89 [2.42-6.25], p<0.0001). Using our recursive partitioning tree, we were able to distinguish 5 subgroups of TNBC patients with different prognosis. For patients without lymph node involvement after NAC, obesity was significantly associated with a poor prognosis (HR = 2.64 [1.28-5.55]). As for patients with lymph node involvement after NAC, the pre-menopausal status in grade III tumors was associated with poor prognosis (HR = 9.68 [5.71-18.31]). Conclusion This study demonstrates that axillary lymph node status after NAC is the major prognostic factor for triple-negative breast cancers. Moreover, we identified body mass index and menopausal status as two other promising prognostic factors in this breast cancer subgroup. Using these clinical factors, we were able to classify TNBC patients in 5 subgroups, for which pre-menopausal patients with grade III tumors and lymph node involvement after NAC have the worse prognosis.
引用
收藏
页数:15
相关论文
共 42 条
[21]
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer [J].
Liedtke, Cornelia ;
Mazouni, Chafika ;
Hess, Kenneth R. ;
Andre, Fabrice ;
Tordai, Attila ;
Mejia, Jaime A. ;
Symmans, W. Fraser ;
Gonzalez-Angulo, Ana M. ;
Hennessy, Bryan ;
Green, Marjorie ;
Cristofanilli, Massimo ;
Hortobagyi, Gabriel N. ;
Pusztai, Lajos .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (08) :1275-1281
[22]
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy [J].
Loibl, Sibylle ;
Mueller, Berit Maria ;
von Minckwitz, Gunter ;
Schwabe, Michael ;
Roller, Marc ;
Darb-Esfahani, Silvia ;
Ataseven, Beyhan ;
du Bois, Andreas ;
Fissler-Eckhoff, Annette ;
Gerber, Bernd ;
Kulmer, Uwe ;
Alles, Jens-Uwe ;
Mehta, Keyur ;
Denkert, Carsten .
BREAST CANCER RESEARCH AND TREATMENT, 2011, 130 (02) :477-487
[23]
Molecular links between obesity and breast cancer [J].
Lorincz, A. M. ;
Sukumar, S. .
ENDOCRINE-RELATED CANCER, 2006, 13 (02) :279-292
[24]
Commentary: Chemotherapy Dosing in Obese Patients With Cancer-The Need for Evidence-Based Clinical Practice Guidelines [J].
Lyman, Gary H. .
JOURNAL OF ONCOLOGY PRACTICE, 2011, 7 (01) :17-17
[25]
Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes [J].
Lyman, Gary H. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2009, 7 (01) :99-108
[26]
Epidemiology of basal-like breast cancer [J].
Millikan, Robert C. ;
Newman, Beth ;
Tse, Chiu-Kit ;
Moorman, Patricia G. ;
Conway, Kathleen ;
Smith, Lisa V. ;
Labbok, Miriam H. ;
Geradts, Joseph ;
Bensen, Jeannette T. ;
Jackson, Susan ;
Nyante, Sarah ;
Livasy, Chad ;
Carey, Lisa ;
Earp, H. Shelton ;
Perou, Charles M. .
BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (01) :123-139
[27]
Body Size, Physical Activity, and Risk of Triple-Negative and Estrogen Receptor-Positive Breast Cancer [J].
Phipps, Amanda I. ;
Chlebowski, Rowan T. ;
Prentice, Ross ;
McTiernan, Anne ;
Stefanick, Marcia L. ;
Wactawski-Wende, Jean ;
Kuller, Lewis H. ;
Adams-Campbell, Lucile L. ;
Lane, Dorothy ;
Vitolins, Mara ;
Kabat, Geoffrey C. ;
Rohan, Thomas E. ;
Li, Christopher I. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2011, 20 (03) :454-463
[28]
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer [J].
Pierga, JY ;
Mouret, E ;
Diéras, V ;
Laurence, V ;
Beuzeboc, P ;
Dorval, T ;
Palangié, T ;
Jouve, M ;
Vincent-Salomon, A ;
Scholl, S ;
Extra, JM ;
Asselain, B ;
Pouillart, P .
BRITISH JOURNAL OF CANCER, 2000, 83 (11) :1480-1487
[29]
Rakha E.A., 2007, Prognostic markers in triple-negative breast cancer, V109, P25, DOI [10.1002/cncr.22381, DOI 10.1002/CNCR.22381]
[30]
Prognostic markers in triple-negative breast cancer [J].
Rakha, Emad A. ;
El-Sayed, Maysa E. ;
Green, Andrew R. ;
Lee, Andrew H. S. ;
Robertson, John F. ;
Ellis, Ian O. .
CANCER, 2007, 109 (01) :25-32